Stock comparison
BioMarin Pharmaceutical
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BMRN
BioMarin Pharmaceutical
Market cap
$10.45B
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BMRN | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 58D | 66C | RPRX |
| Benjamin Graham | 57D | 84A | RPRX |
| Philip Fisher | 55C | 65C | RPRX |
| Peter Lynch | 47D | 60C | RPRX |
| Joel Greenblatt | 28F | 40D | RPRX |
| Charlie Munger | 45D | 68D | RPRX |
| Terry Smith | 52D | 58D | RPRX |
Side-by-side metrics
| Metric | BMRN | RPRX |
|---|---|---|
| Market cap | $10.45B | $23.44B |
| P/E (TTM) | 38.7x | 27.6x |
| EV/EBIT | 18.1x | 19.9x |
| ROIC (TTM) | 3.92% | 8.43% |
| Gross margin | 75.93% | 99.95% |
| Net margin | 8.29% | 33.91% |
| Revenue CAGR 5y | 14.93% | 0.96% |
| EPS CAGR 5y | 2.29% | 11.83% |
| Debt / Equity | 0.2x | 1.3x |
| Dividend yield | 0.0% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BMRN leads on
- EPS CAGR 5y2.29%vs 11.83%+95%
- Revenue CAGR 5y14.93%vs 0.96%+94%
- Debt / Equity0.2xvs 1.3x+82%
- EV/EBIT18.1xvs 19.9x+9%
RPRX leads on
- Dividend yield1.72%vs 0.0%+100%
- Net margin33.91%vs 8.29%+76%
- Market cap$23.44Bvs $10.45B+55%
- ROIC (TTM)8.43%vs 3.92%+54%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.